Life in the Lab

The COVID-19 deluge: Is it time for a new model of data disclosure?

Ken Hallenbeck
July 15, 2020

In the first five months of 2020, PubMed indexed 11,580 results for the keyword “COVID-19.” The number of articles in the National Center for Biotechnology Information’s archive increased steadily from 224 in December 2019 to nearly 7,000 in May. This deluge of scientific papers related to the pandemic provides a unique opportunity to review the core assumptions of the modern publication model.

COVID-19-entries-445x369.jpg
Ken Hallenbeck
NCBI PubMed search results for “COVID-19” in 2020. Counts were identified by searching for articles with publication dates in each month.

As scientists turn their attention to understanding the novel coronavirus that causes COVID-19, the publishing system has adapted to rapidly disseminate COVID-19–related findings. For example, the first scientific report of a COVID-19 infection in the U.S. was published online in the New England Journal of Medicine on Jan. 31, just one day after the final clinical data were collected. Researchers and public health officials around the country needed these data to prepare for the outbreak; the work was cited more than 1,400 times in the four months after it was posted.

Rapid disclosure of data should not be limited to international health crises. The scientific community can use data only after they are disclosed, so why do months or years elapse between when data are collected and when they are shared? The benefits of reducing this delay are obvious in the case of COVID-19, but the same principle applies to all data.

The path to a scientific literature that rapidly and consistently captures all the data we generate is far from clear. In seeking such a path, I’ve looked at the success of preprinting in accelerating manuscript disclosure.

Rebalancing to make room for data

Uploading manuscripts to preprint servers such as bioRxiv and chemRxiv speeds up the communication of work headed to peer review and publication. Preprinting also reframes the value of manuscripts: By disseminating submission drafts, authors acknowledge that the work therein is worth sharing with the scientific community regardless of peer review outcome. What preprinting accomplishes for manuscript drafts is also possible for stand-alone data.

Successful data-centric efforts within the life sciences include depositories such as the Protein Data Bank and Sequence Read Archive as well as publishing reform efforts such as Wellcome Open Research and the Structural Genomic Consortium’s Open Lab Notebooks. But the idea that data can be collected and reported without a pitch about the data’s implications has not been adopted widely. What would it look like if we shifted to reporting data for its own sake rather than solely in the framework of story-driven manuscripts?

Introducing data disclosure articles

I envision a future when results of experimental work can be preprinted or published separately from traditional journal articles. These new manuscripts would consist of polished data from a single study or related research questions. They could report the results of compound screens, preparation of valuable or challenging reagents, the structural model for a protein, bioinformatics tools, sequencing efforts or any field-specific minimum publishable unit of research work. These data represent additions to a field regardless of whether they motivate future studies or ever are included in traditional journal articles.

Data disclosure articles would not require peer review because they would not include discussion about the implications of the work. If not falsified or manipulated, data have objective value. While removing peer review from scientific publication is controversial, the scientific community can learn something even from poorly executed and communicated experiments; this often occurs regardless of peer review. While the threat of a reviewer’s close inspection may motivate more robust experiments, data articles would not be generated in a vacuum: They also would become pieces of traditional peer-reviewed journal articles. With this model, however, data disclosure does not wait for authors to generate an analysis.

Peer review evaluates whether a traditional journal article’s claims are supported by the data the authors include and cite. In my proposed model, the data can be preprinted and are not under review; rather, when a paper is submitted, the claims based on the data will be reviewed. By separating peer review from data disclosure, readers will see more clearly that the data and the claims based on those data are interacting but independent.

Reporting data in smaller, separate manuscripts has several advantages: 

  1. These reports could appear in real time as larger projects advance. Others in the field could provide feedback on ongoing studies rather than retroactive analysis of work completed over many years.
  2. Data articles would be free from conjecture and meta-analysis as well as from the bias introduced by a journal’s reputation.
  3. Lowering the barrier to data disclosure would allow what are now unpublishable projects, such as replication studies or good ideas that didn’t pan out, to reach the broader scientific community.
  4. Reducing the time to disclosure might motivate pharmaceutical companies to share data that is tangential to their drug-discovery pipelines.

Potential pitfalls

Scientific literature is inundated with over 2 million unique manuscripts per year. Some people might argue that lowering the barrier to data disclosure only will increase this volume and could lead to publication of incomplete or poorly executed work. Without analysis by authors and reviewers, impactful data could be lost in the noise. In highly competitive fields, authors might hesitate to report results before a journal guarantees publication of the related article. To protect against these pitfalls, researchers will need to work toward a collective understanding of the minimum publishable unit and agree that preprinted data articles represent meaningful contributions to the scientific literature. Individual fields may need to develop new tools to curate and index data articles to aid in dissemination. These are challenging barriers, but if authors integrate this new model for data disclosure with the existing publishing mechanisms, their audience will be able both to gain access to data quickly and to appreciate novel findings.

First steps

To begin adopting this new model for data disclosure, I suggest authors preprint concise articles with an emphasis on the data presented. This will build momentum toward a publishing environment that encourages data disclosure as a necessary and independent scientific achievement. In this environment, all researchers, and the scientific enterprise, could function more effectively.

Scientists produce two things of separate but equal value: data and interpretation of that data. There is no reason our publication system should emphasize one of these at the cost of the other.

Enjoy reading ASBMB Today?

Become a member to receive the print edition monthly and the digital edition weekly.

Learn more
Ken Hallenbeck

Ken Hallenbeck earned a Ph.D. in pharmaceutical sciences from the University of California, San Francisco, and now is an early drug-discovery researcher. He serves on the board of directors of ReImagine Science and is the life sciences lead at TerraPrime.

Related articles

COVID-19, preprints and journalists
Alice Fleerackers & Lauren A. Maggio
From the journals: MCP
Nivedita Uday Hegdekar

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Opinions

Opinions highlights or most popular articles

Evolutionary constraints on disordered proteins
Feature

Evolutionary constraints on disordered proteins

Dec. 5, 2022

Best of BMB 2022: “There’s evidence that there must be conservation of function — so how does this happen, if the sequence changes so much?”

Fun in Seattle
President's Message

Fun in Seattle

Dec. 1, 2022

#DiscoverBMB 2023: Come to Seattle for the science. Stay for the aquarium!

The f -word (failure) in research: When good plans go bad
Books

The f -word (failure) in research: When good plans go bad

Nov. 29, 2022

This is an edited excerpt from “Life and Research: A Survival Guide for Early-Career Biomedical Scientists,” a book that started as a tweet, according to its authors.

Proteins for a green energy future
Essay

Proteins for a green energy future

Nov. 20, 2022

“We need giant steps, not small, if we are going to create the innovation in policies, political will, and technology needed to succeed with this existential problem,” writes Vanderbilt’s Borden Lacy.

A glimpse into the world of lipids
Interview

A glimpse into the world of lipids

Nov. 18, 2022

ASBMB’s Deuel conference provides "a bird’s-eye view of the field."’

Advocacy successes in 2022
Funding

Advocacy successes in 2022

Nov. 17, 2022

Here’s some of what the ASBMB Public Affairs Advisory Committee and public affairs department have been up to over the past year.